Literature DB >> 31351362

How do actors with asymmetrical power assert authority in policy agenda-setting? A study of authority claims by health actors in trade policy.

Belinda Townsend1, Ashley Schram2, Ronald Labonté3, Fran Baum4, Sharon Friel5.   

Abstract

How health advocates and industry actors attempt to assert their authority as a strategy of influence in policymaking remains underexplored in the health governance literature. Greater exploration of the kinds of authority sources used by health actors vis-à-vis market actors and the role ideational factors may play in shaping access to these sources provides insight into advocates' efforts to exert influence in policy forums. Using the trade domain in Australia as a case study of the way in which the commercial determinants of health operate, we examined the different ways in which health, public interest and market actors assert their authority. Drawing on a political science typology of authority, we analysed 87 submissions to the Australian government during the Trans-Pacific Partnership negotiations. We identify four types of authority claims; institutional authority, derived from holding a position of influence within another established institution; legal authority through appeals to legal agreements and precedents; networked authority through cross-referencing between actors, and expert authority through use of evidence. Combining these claims with a framing analysis, we found that these bases of authority were invoked differently by actors who shared the dominant neoliberal ideology in contrast to those actors that shared a public interest discourse. In particular, market actors were much less likely to rely on external sources of authority, while health and public interest actors were more likely to appeal to networked and expert authority. We argue that actors who share strong ideational alignment with the dominant policy discourse appear less reliant on other sources of authority. Implications of this analysis include the need for greater attention to the different strategies and ideas used by industry and public health organisations in trade policy agenda-setting for health, which ultimately enable or constrain the advancement of health on government agendas.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Keywords:  Agenda-setting; Authority; Commercial determinants of health; Non-state actors; Policy advocacy; Public health; Trade and health; Trans-Pacific partnership

Year:  2019        PMID: 31351362     DOI: 10.1016/j.socscimed.2019.112430

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  5 in total

1.  Corporate power and the international trade regime preventing progressive policy action on non-communicable diseases: a realist review.

Authors:  Penelope Milsom; Richard Smith; Phillip Baker; Helen Walls
Journal:  Health Policy Plan       Date:  2021-05-17       Impact factor: 3.344

2.  What Generates Attention to Health in Trade Policy-Making? Lessons From Success in Tobacco Control and Access to Medicines: A Qualitative Study of Australia and the (Comprehensive and Progressive) Trans-Pacific Partnership.

Authors:  Belinda Townsend; Sharon Friel; Ashley Schram; Fran Baum; Ronald Labonté
Journal:  Int J Health Policy Manag       Date:  2021-10-01

3.  Health Inequality as a Large-Scale Outcome of Complex Social Systems: Lessons for Action on the Sustainable Development Goals.

Authors:  Anna Matheson
Journal:  Int J Environ Res Public Health       Date:  2020-04-14       Impact factor: 3.390

4.  Advancing a health equity agenda across multiple policy domains: a qualitative policy analysis of social, trade and welfare policy.

Authors:  Belinda Townsend; Sharon Friel; Toby Freeman; Ashley Schram; Lyndall Strazdins; Ronald Labonte; Tamara Mackean; Fran Baum
Journal:  BMJ Open       Date:  2020-11-06       Impact factor: 2.692

5.  Who influences nutrition policy space using international trade and investment agreements? A global stakeholder analysis.

Authors:  Kelly Garton; Boyd Swinburn; Anne Marie Thow
Journal:  Global Health       Date:  2021-10-02       Impact factor: 4.185

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.